Immunomodulatory role of Interleukin-33 in large vessel vasculitis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 04 2020
14 04 2020
Historique:
received:
10
10
2019
accepted:
25
02
2020
entrez:
15
4
2020
pubmed:
15
4
2020
medline:
25
11
2020
Statut:
epublish
Résumé
The mechanisms regulating inflammation in large vessels vasculitis (LVV) are poorly understood. Interleukin 33 (IL-33) has been shown to license innate and adaptive immunity by enhancing Th2 cytokines production. We aimed to examine the role of IL-33 in the immunomodulation of T cell activation in LVV. T cell homeostasis and cytokines production were determined in peripheral blood from 52 patients with giant cell arteritis (GCA) and 50 healthy donors (HD), using Luminex assay, flow cytometry, quantitative RT-PCR and by immunofluorescence analysis in inflammatory aorta lesions. We found increased level of IL-33 and its receptor ST2/IL-1R4 in the serum of patient with LVV. Endothelial cells were the main source of IL-33, whereas Th2 cells, Tregs and mast cells (MC) express ST2 in LVV vessels. IL-33 had a direct immunomodulatory impact by increasing Th2 and Tregs. IL-33 and MC further enhanced Th2 and regulatory responses by inducing a 6.1 fold increased proportion of Tregs (p = 0.008). Stimulation of MC by IL-33 increased indoleamine 2 3-dioxygenase (IDO) activity and IL-2 secretion. IL-33 mRNA expression was significantly correlated with the expression of IL-10 and TGF-β within aorta inflammatory lesions. To conclude, our findings suggest that IL-33 may exert a critical immunoregulatory role in promoting Tregs and Th2 cells in LVV.
Identifiants
pubmed: 32286393
doi: 10.1038/s41598-020-63042-3
pii: 10.1038/s41598-020-63042-3
pmc: PMC7156501
doi:
Substances chimiques
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Interleukin-33
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6405Références
Watanabe, R., Zhang, H., Berry, G., Goronzy, J. J. & Weyand, C. M. Immune checkpoint dysfunction in large and medium vessel vasculitis. Am. J. Physiol. Heart Circ. Physiol. 312, H1052–H1059 (2017).
doi: 10.1152/ajpheart.00024.2017
Saadoun, D. et al. Th1 and Th17 cytokines drive Takayasu Arteritis inflammation. Arthritis Rheumatol. Hoboken NJ, https://doi.org/10.1002/art.39037 (2015).
Deng, J., Younge, B. R., Olshen, R. A., Goronzy, J. J. & Weyand, C. M. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121, 906–915 (2010).
doi: 10.1161/CIRCULATIONAHA.109.872903
Weyand, C. M. & Goronzy, J. J. Immune mechanisms in medium and large-vessel vasculitis. Nat. Rev. Rheumatol. 9, 731–740 (2013).
doi: 10.1038/nrrheum.2013.161
Terrier, B. et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. 64, 2001–2011 (2012).
doi: 10.1002/art.34327
Ciccia, F. et al. IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. Ann. Rheum. Dis. 72, 258–264 (2013).
doi: 10.1136/annrheumdis-2012-201309
Márquez, A. et al. A candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCA. PloS One 9, e113476 (2014).
doi: 10.1371/journal.pone.0113476
Cayrol, C. & Girard, J.-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr. Opin. Immunol. 31, 31–37 (2014).
doi: 10.1016/j.coi.2014.09.004
Al, L. J. et al. Interleukin-33 prevents the development of autoimmune diabetes in NOD mice. - PubMed - NCBI., https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/30780005 .
Takatori, H., Makita, S., Ito, T., Matsuki, A. & Nakajima, H. Regulatory Mechanisms of IL-33-ST2-Mediated Allergic Inflammation. Front. Immunol. 9, 2004 (2018).
doi: 10.3389/fimmu.2018.02004
Chen, W.-Y., Tsai, T.-H., Yang, J.-L. & Li, L.-C. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 49, 349–358 (2018).
doi: 10.1159/000492885
Pavlovic, S. et al. IL-33 Prevents MLD-STZ Induction of Diabetes and Attenuate Insulitis in Prediabetic NOD Mice. Front. Immunol. 9, 2646 (2018).
doi: 10.3389/fimmu.2018.02646
Griesenauer, B. & Paczesny, S. The ST2/iL-33 Axis in immune Cells during inflammatory Diseases. Front. Immunol. 8 (2017).
Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 33, 1122–1128 (1990).
doi: 10.1002/art.1780330810
The American College of Rheumatology criteria for the classification of Takayasu arteritis. - PubMed – NCBI, https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/1975175 (1990).
Saleh, R. et al. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood 124, 111–120 (2014).
doi: 10.1182/blood-2013-10-534685
Maneglier, B. et al. Simultaneous measurement of kynurenine and tryptophan in human plasma and supernatants of cultured human cells by HPLC with coulometric detection. Clin. Chem. 50, 2166–2168 (2004).
doi: 10.1373/clinchem.2004.037465
Peine, M., Marek, R. M. & Löhning, M. IL-33 in T Cell Differentiation, Function, and Immune Homeostasis. Trends Immunol. 37, 321–333 (2016).
doi: 10.1016/j.it.2016.03.007
Chan, B. C. L., Lam, C. W. K., Tam, L.-S. & Wong, C. K. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Front. Immunol. 10, 364 (2019).
doi: 10.3389/fimmu.2019.00364
Liew, F. Y., Girard, J.-P. & Turnquist, H. R. Interleukin-33 in health and disease. Nat. Rev. Immunol. 16, 676–689 (2016).
doi: 10.1038/nri.2016.95
Liew, F. Y., Pitman, N. I. & McInnes, I. B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10, 103–110 (2010).
doi: 10.1038/nri2692
Schiering, C. et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513, 564–568 (2014).
doi: 10.1038/nature13577
Orabona, C. & Grohmann, U. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol. Biol. Clifton NJ 677, 269–280 (2011).
doi: 10.1007/978-1-60761-869-0_19
Xu, D. et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. 105, 10913–10918 (2008).
doi: 10.1073/pnas.0801898105
Lu, L.-F. et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442, 997–1002 (2006).
doi: 10.1038/nature05010
Rodrigues, C. P. et al. Tolerogenic IDO+ dendritic cells are induced by PD-1-expressing mast cells. Front. Immunol. 7 (2016).
Leveson-Gower, D. B. et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood 122, 3659–3665 (2013).
doi: 10.1182/blood-2013-08-519157
Morita, H. et al. An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. Immunity 43, 175–186 (2015).
doi: 10.1016/j.immuni.2015.06.021